Literature DB >> 33406413

Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.

Rayzel C Fernandes1, John Toubia2, Scott Townley1, Adrienne R Hanson1, B Kate Dredge3, Katherine A Pillman3, Andrew G Bert3, Jean M Winter1, Richard Iggo4, Rajdeep Das5, Daisuke Obinata6, Shahneen Sandhu7, Gail P Risbridger8, Renea A Taylor9, Mitchell G Lawrence10, Lisa M Butler11, Amina Zoubeidi12, Philip A Gregory13, Wayne D Tilley1, Theresa E Hickey1, Gregory J Goodall14, Luke A Selth15.   

Abstract

Potent therapeutic inhibition of the androgen receptor (AR) in prostate adenocarcinoma can lead to the emergence of neuroendocrine prostate cancer (NEPC), a phenomenon associated with enhanced cell plasticity. Here, we show that microRNA-194 (miR-194) is a regulator of epithelial-neuroendocrine transdifferentiation. In clinical prostate cancer samples, miR-194 expression and activity were elevated in NEPC and inversely correlated with AR signaling. miR-194 facilitated the emergence of neuroendocrine features in prostate cancer cells, a process mediated by its ability to directly target a suite of genes involved in cell plasticity. One such target was FOXA1, which encodes a transcription factor with a vital role in maintaining the prostate epithelial lineage. Importantly, a miR-194 inhibitor blocked epithelial-neuroendocrine transdifferentiation and inhibited the growth of cell lines and patient-derived organoids possessing neuroendocrine features. Overall, our study reveals a post-transcriptional mechanism regulating the plasticity of prostate cancer cells and provides a rationale for targeting miR-194 in NEPC.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FOXA1; lineage plasticity; miR-194; microRNA; neuroendocrine prostate cancer; post-transcriptional gene regulation; prostate cancer; transdifferentiation

Mesh:

Substances:

Year:  2021        PMID: 33406413     DOI: 10.1016/j.celrep.2020.108585

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  8 in total

Review 1.  Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives.

Authors:  Francesco Pinto; Francesco Dibitetto; Mauro Ragonese; Pierfrancesco Bassi
Journal:  Med Sci (Basel)       Date:  2022-04-28

Review 2.  Interaction between Non-Coding RNAs and Androgen Receptor with an Especial Focus on Prostate Cancer.

Authors:  Mohammad Taheri; Tayyebeh Khoshbakht; Elena Jamali; Julia Kallenbach; Soudeh Ghafouri-Fard; Aria Baniahmad
Journal:  Cells       Date:  2021-11-16       Impact factor: 6.600

Review 3.  Role of MicroRNAs in Neuroendocrine Prostate Cancer.

Authors:  Amritha Sreekumar; Sharanjot Saini
Journal:  Noncoding RNA       Date:  2022-03-30

4.  The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.

Authors:  Valeria A Copello; Kerry L Burnstein
Journal:  Oncogene       Date:  2022-04-13       Impact factor: 8.756

Review 5.  Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate cancer.

Authors:  Hengfeng Zhou; Qiangrong He; Chao Li; Bassam Lutf Mohammed Alsharafi; Liang Deng; Zhi Long; Yu Gan
Journal:  Front Cell Dev Biol       Date:  2022-07-22

Review 6.  Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.

Authors:  Eva Slabáková; Zuzana Kahounová; Jiřina Procházková; Karel Souček
Journal:  Noncoding RNA       Date:  2021-12-02

7.  High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids.

Authors:  Nicholas Choo; Susanne Ramm; Jennii Luu; Jean M Winter; Luke A Selth; Amy R Dwyer; Mark Frydenberg; Jeremy Grummet; Shahneen Sandhu; Theresa E Hickey; Wayne D Tilley; Renea A Taylor; Gail P Risbridger; Mitchell G Lawrence; Kaylene J Simpson
Journal:  SLAS Discov       Date:  2021-06-11       Impact factor: 3.341

Review 8.  Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.

Authors:  Stefan Werner; Gunhild von Amsberg; Lina Merkens; Verena Sailer; Davor Lessel; Ella Janzen; Sarah Greimeier; Jutta Kirfel; Sven Perner; Klaus Pantel
Journal:  J Exp Clin Cancer Res       Date:  2022-02-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.